# A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

> **NCT06062420** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 316 (actual)

## Conditions studied

- Neoplasms, Head and Neck

## Interventions

- **DRUG:** Dostarlimab
- **DRUG:** Belrestotug
- **DRUG:** Nelistotug
- **DRUG:** Remzistotug

## Key facts

- **NCT ID:** NCT06062420
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-14
- **Primary completion:** 2026-09-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 316 (ACTUAL)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06062420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06062420, "A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06062420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*